Literature DB >> 8783497

The neglected role of type I interferon in the T-cell response: implications for its clinical use.

F Belardelli1, I Gresser.   

Abstract

Originally described as an antiviral substance, type I interferon (IFN) was subsequently shown to exert multiple biological effects and is now the most frequently used cytokine in the treatment of some viral and neoplastic diseases. Although early studies described various effects on the immune system, the role of type I IFN as an immunoregulatory molecule has long been neglected. Here, Filippo Belardelli and Ion Gresser summarize recent experimental results on the interactions of type I IFN with T cells, which may prove important in its use in patients.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8783497     DOI： 10.1016/0167-5699(96)10027-X

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  48 in total

1.  Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells.

Authors:  P Monini; F Carlini; M Stürzl; P Rimessi; F Superti; M Franco; G Melucci-Vigo; A Cafaro; D Goletti; C Sgadari; S Butto'; P Leone; C Chiozzini; C Barresi; A Tinari; A Bonaccorsi; M R Capobianchi; M Giuliani; A di Carlo; M Andreoni; G Rezza; B Ensoli
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 2.  Role of cytokines in the innate immune response to intracellular pathogens.

Authors:  S Stenger; M Röllinghoff
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

3.  Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.

Authors:  H Xiao; C Neuveut; H L Tiffany; M Benkirane; E A Rich; P M Murphy; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

4.  The presence of alpha interferon at the time of infection alters the innate and adaptive immune responses to porcine reproductive and respiratory syndrome virus.

Authors:  Susan L Brockmeier; Crystal L Loving; Eric A Nelson; Laura C Miller; Tracy L Nicholson; Karen B Register; Marvin J Grubman; Douglas E Brough; Marcus E Kehrli
Journal:  Clin Vaccine Immunol       Date:  2012-02-01

5.  Antiviral treatment with alpha interferon up-regulates CD14 on liver macrophages and its soluble form in patients with chronic hepatitis B.

Authors:  Patrizia Carotenuto; Debby van Riel; André Artsen; Sven Bruijns; Fons G Uytdehaag; Jon D Laman; Andeltje B van Nunen; Pieter E Zondervan; Robert A De Man; Albert D Osterhaus; Oscar Pontesilli
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.

Authors:  H Tada; D J Maron; E A Choi; J Barsoum; H Lei; Q Xie; W Liu; L Ellis; A D Moscioni; J Tazelaar; S Fawell; X Qin; K J Propert; A Davis; D L Fraker; J M Wilson; F R Spitz
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

7.  A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Authors:  Anje Cauwels; Sandra Van Lint; Geneviève Garcin; Jennyfer Bultinck; Franciane Paul; Sarah Gerlo; José Van der Heyden; Yann Bordat; Dominiek Catteeuw; Lode De Cauwer; Elke Rogge; Annick Verhee; Gilles Uzé; Jan Tavernier
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

8.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

9.  Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.

Authors:  I Kötter; A K Eckstein; N Stübiger; M Zierhut
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

10.  Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice.

Authors:  X Q Qin; N Tao; A Dergay; P Moy; S Fawell; A Davis; J M Wilson; J Barsoum
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.